TD Cowen lowered shares of Despegar.com (NYSE:DESP – Free Report) from a buy rating to a sell rating in a research note released on Monday, Marketbeat reports. TD Cowen currently has $14.00 price objective on the stock, up from their previous price objective of $12.00.
Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $17.00 price objective on shares of Despegar.com in a research note on Friday, August 16th.
Get Our Latest Report on Despegar.com
Despegar.com Price Performance
Institutional Investors Weigh In On Despegar.com
Several hedge funds and other institutional investors have recently made changes to their positions in DESP. Bayesian Capital Management LP bought a new stake in shares of Despegar.com in the first quarter valued at approximately $132,000. Tidal Investments LLC bought a new stake in Despegar.com in the 1st quarter valued at $4,534,000. Adalta Capital Management LLC bought a new stake in Despegar.com in the 1st quarter valued at $120,000. SkyView Investment Advisors LLC grew its position in Despegar.com by 2.1% in the 1st quarter. SkyView Investment Advisors LLC now owns 232,579 shares of the company’s stock worth $2,782,000 after purchasing an additional 4,727 shares during the last quarter. Finally, Woodson Capital Management LP bought a new position in shares of Despegar.com during the 1st quarter worth about $5,980,000. 67.93% of the stock is owned by institutional investors and hedge funds.
About Despegar.com
Despegar.com, Corp., an online travel company, provides a range of travel and travel-related products to leisure and corporate travelers through its websites and mobile applications in Latin America and the United States. The company operates in two segments, Travel Business and Financial Services Business.
Read More
- Five stocks we like better than Despegar.com
- Technology Stocks Explained: Here’s What to Know About Tech
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What is the Australian Securities Exchange (ASX)
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Despegar.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Despegar.com and related companies with MarketBeat.com's FREE daily email newsletter.